Novartis AG
NVSEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $193,929,800 | $209,693,904 | $189,893,560 | $185,934,063 |
| - Cash | $11,459,000 | $13,393,000 | $7,517,000 | $12,407,000 |
| + Debt | $31,258,000 | $26,348,000 | $27,964,000 | $31,093,000 |
| Enterprise Value | $213,728,800 | $222,648,904 | $210,340,560 | $204,620,063 |
| Revenue | $51,722,000 | $46,660,000 | $51,828,000 | $52,877,000 |
| % Growth | 10.8% | -10% | -2% | – |
| Gross Profit | $38,895,000 | $34,640,000 | $36,342,000 | $37,010,000 |
| % Margin | 75.2% | 74.2% | 70.1% | 70% |
| EBITDA | $20,715,000 | $19,517,830 | $15,209,122 | $17,168,447 |
| % Margin | 40.1% | 41.8% | 29.3% | 32.5% |
| Net Income | $11,941,000 | $14,850,000 | $6,955,000 | $24,021,000 |
| % Margin | 23.1% | 31.8% | 13.4% | 45.4% |
| EPS Diluted | 5.87 | 7.58 | 3.27 | 10.65 |
| % Growth | -22.6% | 131.8% | -69.3% | – |
| Operating Cash Flow | $17,619,000 | $14,458,000 | $14,236,000 | $15,071,000 |
| Capital Expenditures | -$3,814,000 | -$2,753,000 | -$2,671,000 | -$2,971,000 |
| Free Cash Flow | $13,805,000 | $11,705,000 | $11,565,000 | $12,100,000 |